摘要:
The present invention relates to an indole amide compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.
摘要:
Disclosed are a method for preparing a target recombinant protein with modulated galactosylation or a method for modulating the galactosylation of a target recombinant protein, including increasing the osmolality of a culture solution of animal cells which express a target recombinant protein during the animal cell culture; a method for preparing a target recombinant protein with modulated galactosylation or a method for modulating the galactosylation of a target recombinant protein, including supplementing asparagine to a culture solution of animal cells which express a target recombinant protein during the animal cell culture; a method for preparing a target recombinant protein with modulated galactosylation or a method for modulating the galactosylation of a target recombinant protein, including increasing the osmolality of an animal cell culture which expresses a target recombinant protein and supplementing asparagine thereto during the animal cell culture; and a target recombinant protein with modulated galactosylation, which is prepared by the method.
摘要:
Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative.
摘要:
The present invention relates to a pharmaceutical composition including valsartan and rosuvastatin calcium as active ingredients, and a manufacturing method therefor. The pharmaceutical composition including valsartan and rosuvastatin calcium according to the present invention can alleviate side effects of the existing single preparations and simultaneously improve compliance of patients having a cardiovascular disease, a hyperlipidemic disease and a complex disease thereof, and increases treatment and prevention effects, and in particular, obtains synergistic effects in treating hyperlipidemia, and enhances the dissolution rate of valsartan and rosuvastatin calcium and treatment effects by granulating valsartan and mixing rosuvastatin calcium.
摘要:
The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.
摘要:
The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis (trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-di-fluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.